Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.67 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1748811 | 0.99 | HTR6 (0.66) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL475562 | 0.93 | HTR6 (0.67) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| Hydrochloric Acid SCHEMBL1748394 | 0.92 | HTR6 (0.66) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL1747990 | 0.81 | HTR6 (0.68) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL5021091 | 0.81 | HTR6 (0.65) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL1748828 | 0.81 | HTR6 (0.42) | HTR6CYP2C9 | |
| Hydrochloric Acid SCHEMBL1748809 | 0.81 | HTR6 (0.67) | HTR6SOS1HPGDSMN1; SMN2ADRB1 | |
| SCHEMBL475397 | 0.80 | HTR6 (1.00) | HTR6SOS1HPGDSMN1; SMN2HTR1A | |
| SCHEMBL1748904 | 0.80 | HTR6 (1.00) | HTR6SOS1HPGDSMN1; SMN2HTR1A | |
| SCHEMBL1748316 | 0.80 | HTR6 (1.00) | HTR6SOS1HPGDSMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | claimed |
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HTR6 1/4885SOS1 3087/4885HPGD 2326/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | HTR6 1/4885SOS1 3087/4885HPGD 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.